Biomedical Diagnostics to develop breast cancer test
This article was originally published in Clinica
Two companies jointly funding and developing an early diagnostic test for breast cancer have formed a commercial company to take the idea further. Biotherapies of Ann Arbor, Michigan and BioLabs, based in New York, have launched Biomedical Diagnostics, with BioLabs providing initial funding of $1.5 million. The two companies have been co-operating since the beginning of the year.
You may also be interested in...
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.